CN104873478A - Tamsulosin hydrochloride sustained-release capsule and preparation method thereof - Google Patents
Tamsulosin hydrochloride sustained-release capsule and preparation method thereof Download PDFInfo
- Publication number
- CN104873478A CN104873478A CN201510309268.8A CN201510309268A CN104873478A CN 104873478 A CN104873478 A CN 104873478A CN 201510309268 A CN201510309268 A CN 201510309268A CN 104873478 A CN104873478 A CN 104873478A
- Authority
- CN
- China
- Prior art keywords
- tamsulosin hydrochloride
- release
- sustained
- coating
- slow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a tamsulosin hydrochloride sustained-release capsule and a preparation method thereof. Hydroxypropyl-beta-cyclodextrin is added in a prescription, so as to form clathrate compounds on the outer part of tamsulosin hydrochloride together with the tamsulosin hydrochloride, so that the phenomenon of drug burst release in a drug release process is solved, thereby maintaining stable plasma concentration, reducing the incidence rate of adverse reactions and improving the clinical medication safety. In addition, raw materials are easy to obtain, the preparation process is simple and feasible, the yield is high, the cost is low, industrial mass production can be realized, and obvious economic benefits are achieved.
Description
Technical field
The present invention relates to a kind of oral chemicals slow releasing preparation, be specifically related to a kind of tamsulosin hydrochloride sustained-release capsule and preparation method thereof.
Background technology
Tamsulosin hydrochloride chemical name: (R) (-) 5-{2-[[2-(2-ethoxyphenyl) ether base] amido]-2-methyl }-ethyl-2-methoxybenzenesulphoismide hydrochlorate, molecular formula: C
20h
28n
2o
5sHCl.
Tamsulosin hydrochloride is novel a1 receptor blocking agent, optionally blocks the smooth muscle a1 receptor of neck of bladder, prostate gland and tunicle, reduces smooth muscle tension, reduces lower urinary tract resistance, thus improves the dysuria because prostate hyperplasia causes.Zoopery proves, tamsulosin optionally blocks the epinephrine a1 receptor of rat, rabbit.Its effect is stronger than prazosin 12-22 times, stronger than phentolamine 45-140 times.To people and animal urethra, bladder and the effect of prostatic a1 receptor blocking, stronger than prazosin 2.2-98 times, stronger than phentolamine 40-320 times.Anesthetized dog research display, tamsulosin hydrochloride obviously can reduce the pressure of prostatic, but has no significant effect anesthetized rat rhythmic bladder contraction and intravesical pressure.
Tamsulosin hydrochloride can be used for treating exception caused by prostatic hyperplasia and to urinate symptom, as frequent micturition, nocturia increase, dysuria etc.Because this product reaches therapeutic purposes by improving urethra, neck of bladder and prostatic smooth muscle function, not reduce hypertrophy body of gland, therefore be applicable to light, moderate patient and do not cause serious dysuria person.
About the preparation of domestic tamsulosin hydrochloride sustained-release capsule, domestic also have relevant report, Chinese patent CN103505443A Tamsulosin hydrochloride capsule, it is disclosed that the stable tamsulosin hydrochloride sustained-release capsule of a kind of release, but there is no relevant Data support, the data that final dissolution is also not relevant in the patent.Chinese Patent Application No. 200610030120.1 1 kinds of Tamsulosin hydrochloride capsule and preparation method thereof, by optimized production process and formula, obtain new pharmaceutical preparation, overcome food effect, improve the adaptability of drug safety and patient.
Tamsulosin hydrochloride slow releasing preparation ubiquity result of extraction of the prior art is poor, and there is the prominent shortcoming releasing phenomenon, in long term storage, occur that impurity content raises, certain hidden danger is brought to clinical application, can not play due effect, in addition, preparing, production process in tamsulosin hydrochloride related preparations is complicated, the technology required is higher, is also one of factor limiting the application clinically of this type of medicine and suitability for industrialized production.
Summary of the invention
For the defect of above prior art, the object of this invention is to provide a kind of tamsulosin hydrochloride sustained-release capsule and preparation method thereof, the present inventor by being optimized supplementary product kind and technique, provide a kind of good stability, dissolution high, without burst drug release phenomenon, the simple tamsulosin hydrochloride sustained-release capsule of preparation technology.
In order to realize object of the present invention, inventor analyzes prior art, adopts the direct compression process formulation content uniformity poor, and brings certain potential safety hazard to clinical application.Based on this, inventor expects tamsulosin hydrochloride to be prepared into micro-pill type capsule, successfully solve the problem of uniformity of dosage units difference, further, inventor is in order to improve the dissolution of Tamsulosin hydrochloride capsule, and in medicated layer, add appropriate pH adjusting agent again, dissolution increases really, and tamsulosin hydrochloride is under sour environment, therefore in long term storage, maintain the stability of medicine.
The result of extraction of tamsulosin hydrochloride is better, but absorption process is in vivo slower, tamsulosin hydrochloride is needed to be prepared into slow releasing preparation, inventor is in order to improve tamsulosin hydrochloride dissolution, add appropriate solubilizing agent and find that tamsulosin hydrochloride dissolution time shortens, process in leaching occurs dashing forward and releases phenomenon, easily causes gastrointestinal upset, reduces the compliance of patient.Given this; inventor has attempted a series of protective agent such as HP-β-CD, liposome; find when increasing HP-β-CD in medicated layer; result of extraction and stripping curve steady; namely use HP-β-CD result of extraction good in medicated layer and do not have the prominent phenomenon released, analyzing reason may be after HP-β-CD mixes with tamsulosin hydrochloride, by tamsulosin hydrochloride enclose; form clathrate, control the dispose procedure of tamsulosin hydrochloride.
Specifically, the object of the invention is to be achieved through the following technical solutions:
The invention provides a kind of tamsulosin hydrochloride sustained-release capsule, it is made up of celphere, medicated layer, sustained release coating, and wherein said celphere comprises microcrystalline Cellulose, sorbitol, starch, lactose; Described medicated layer comprises tamsulosin hydrochloride, pH adjusting agent, HP-β-CD, binding agent; Described sustained release coating comprises slow-release material, plasticizer, porogen, antiplastering aid.
Tamsulosin hydrochloride sustained-release capsule of the present invention, each component of this slow releasing capsule presses following weight percents composition:
Above-mentioned proportioning composition is preferably obtained following component ratio, forms by weight percentage:
Above-mentioned proportioning composition is preferably obtained following component ratio, forms by weight percentage:
Wherein, described slow-release material is Eurdragit NE 30, methylcellulose, sodium carboxymethyl cellulose, hypromellose, polyvidone, carbopol, alginic acid sodium salt, chitosan, fat, wax class, stearic acid, hexadecanol, octadecanol, Polyethylene Glycol, ethyl cellulose, polyethylene, polypropylene, polysiloxanes, polysiloxanes, ethylene-vinyl acetate copolymer, polymethyl methacrylate or wherein one or more.
Described binding agent is the one in hypromellose, PVP K30, carboxymethyl cellulose, water, ethanol, starch slurry.
Described pH adjusting agent: one or more in sodium bicarbonate, ammonium bicarbonate, citric acid, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sodium hydrogen phosphate, sodium acetate, fumaric acid.
Described porogen is selected from polyvidone, Polyethylene Glycol, polyvinyl alcohol one.
Described plasticizer is selected from one or more in propylene glycol, Oleum Ricini, Polyethylene Glycol, silicone oil, glycerol, diethyl phthalate or dibutyl ester diethyl phthalate, SA dibutyl ester and tri-n-butyl citrate.
Described antiplastering aid is: the one in micropowder silica gel, silicon dioxide, magnesium stearate, calcium stearate.
Described slow-release material, binding agent, antiplastering aid, porogen, plasticizer, filler carry out that preferably slow-release material is Eurdragit NE 30, binding agent is hypromellose, antiplastering aid is micropowder silica gel, porogen is selected from polyvidone, plasticizer phthalic acid diethylester, filler is HP-β-CD, and described pH adjusting agent is preferably from potassium dihydrogen phosphate.
Another object of the present invention also provides the preparation method of tamsulosin hydrochloride sustained-release capsule, it is characterized in that, concrete operation step is as follows:
(1) get a certain amount of microcrystal cellulose powder, sorbitol, starch, lactose is put in centrifugal granulator, take water as adhesive, obtained 20 order particle diameters are the celphere of 0.5-2mm;
(2) binding agent is made 3 ~ 6%, viscosity is the aqueous solution of 20mpa.s-35mpa.s, and percentage by weight takes in pH adjusting agent, the water-soluble solution of HP-β-CD;
(3) tamsulosin hydrochloride is dissolved in the solution in step (2), slowly stirs, obtain containing drug solns; The concentration of tamsulosin hydrochloride solution is 0.08-0.25% (by weight calculating);
(4) celphere adds fluid bed, with step (3) containing drug solns coating, the pastille piller of obtained tamsulosin hydrochloride after dry;
(5) with 65 ~ 85% dissolve with ethanol solution slow-release material, plasticizer, porogen, antiplastering aid, make sustained release coating liquid;
(6) the pastille piller of tamsulosin hydrochloride adds fluid bed, carry out coating with the coating solution that step (3) obtains, coating weight gain is that 5-15% temperature controls at 38-45 DEG C, is preferably 40 DEG C, coating process answers Keep agitation coating solution, the slow-release pill of obtained tamsulosin hydrochloride after dry;
(7) the tamsulosin hydrochloride slow-release pill that step (6) is obtained is incapsulated, the slow releasing capsule of obtained tamsulosin hydrochloride.
The present invention is better than prior art, be mainly reflected in following some:
(1) the invention provides a kind of tamsulosin hydrochloride sustained-release capsule; appropriate HP-β-CD is added as filler and protective agent in medicated layer; tamsulosin hydrochloride can be wrapped in inside; form new container; solve the prominent of tamsulosin hydrochloride and release phenomenon; thus maintain stable blood drug level, reduce adverse reaction rate, improve clinical drug safety.
(2) add appropriate pH adjusting agent in medicated layer of the present invention, improve the final dissolution of tamsulosin hydrochloride, overcome the defect that in prior art, dissolution is not high.
(3) preparation method of tamsulosin hydrochloride sustained-release capsule provided by the invention, the adjuvant used is easy to get, preparation technology's simple possible, and productive rate is high, cost is low, can realize industrialization large-scale production, has significant economic benefit.
Specific embodiment
By embodiment, above invention is further illustrated, but the present invention is not limited to this.
Embodiment 1
The prescription of celphere and preparation
Get the microcrystalline Cellulose of recipe quantity, sorbitol, starch, lactose is put in centrifugal granulator, take water as adhesive, obtained 20 order particle diameters are the celphere of 0.5-2mm;
The prescription of medicated layer and preparation: 1000 prescriptions
1, take potassium dihydrogen phosphate, HP-β-CD by weight percentage, binding agent is made 2 ~ 6%, viscosity is the aqueous solution of 20mpa.s-35mpa.s;
2, be dissolved in by tamsulosin hydrochloride in the solution in step 1, slowly stir, obtain containing drug solns, wherein by weight calculating, the concentration of tamsulosin hydrochloride solution is 0.08-0.25%;
3, celphere adds fluid bed, with step 2 containing drug solns coating, the pastille piller of obtained tamsulosin hydrochloride after dry;
Coatings prescription and preparation:
4, the pastille piller of tamsulosin hydrochloride adds fluid bed, carries out coating with above-mentioned coating solution, and coating weight gain is 10%, and temperature controls at 40 DEG C, and coating process answers Keep agitation coating solution, the slow-release pill of obtained tamsulosin hydrochloride after dry;
5, tamsulosin hydrochloride slow-release pill is incapsulated, the slow releasing capsule of obtained tamsulosin hydrochloride.
Embodiment 2
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Embodiment 3
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Embodiment 4
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Embodiment 5
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Embodiment 6
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Embodiment 7
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Embodiment 8
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Embodiment 9
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Embodiment 10
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Embodiment 11
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Comparative example 1
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Comparative example 2
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Tamsulosin hydrochloride 0.2g
HP-β-CD 48g
Hypromellose 10g
Coating prescription is as follows:
Preparation method is with embodiment 1.
Comparative example 3
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Comparative example 4
The preparation of celphere is identical with embodiment 1;
The prescription of medicated layer is as follows:
Coating prescription is as follows:
Preparation method is with embodiment 1.
Comparative example 5
1000 prescriptions
Hypromellose and potassium dihydrogen phosphate are dissolved in deionized water by the first step, are mixed with the solution that viscosity is 20mpa.s;
Tamsulosin hydrochloride is dissolved in the obtained solution of the step first step by second step, must contain drug solns;
Celphere is added fluid bed by the 3rd step, and what obtain with second step contains drug solns coating, the pastille piller of obtained tamsulosin hydrochloride after dry;
4th step is soluble in water by triethyl citrate, adds Eudragit NE 30D high-shear emulsion machine emulsifying 5 minutes.
The pastille piller of the tamsulosin hydrochloride of the 4th step is added fluid bed by the 5th step, and the coating solution obtained by step (d) carries out coating, and coating process answers Keep agitation coating solution, the slow-release pill of obtained tamsulosin hydrochloride after dry;
The tamsulosin hydrochloride slow-release pill that step the five step is obtained incapsulates by the 6th step, the slow releasing capsule of obtained tamsulosin hydrochloride.
Comparative example 6
Prepared by ball core
(1) tamsulosin hydrochloride is dissolved in appropriate solvent, mixs homogeneously with microcrystalline Cellulose;
(2) above mixture adds polymer in above-mentioned prescription and necessary adjuvant;
(3) aqueous dispersion adding polymer makes the granule of 1.0mm in centrifugal granulator;
(4) granule made 60 DEG C of dryings 8 hours in air dry oven;
(5) configure the dispersion of coating, add necessary additive;
(6) coating, increases weight as 3-20%;
(7) during tamsulosin hydrochloride coating thing incapsulates.
Comparative example 7
Preparation method:
The preparation of I, blank piller
Get recipe quantity sucrose, starch, dextrin, mixing, enter in centrifugal coating granulator, by centrifugal coating pelletizing method, prior art and technological parameter, prepare blank piller, and size is between 18-26 order;
The preparation of II, slow-release pill
A. recipe quantity tamsulosin hydrochloride and lecithin are dissolved in the alcoholic solution of 50%, after being fully mixed, add recipe quantity polyacrylic resin, appropriate hypromellose, obtain medicament slow release skeleton solution, for subsequent use.
B. by recipe quantity polyethylene glycol 6000 and remaining hypromellose soluble in water, make and bind skeleton agent solution, standby
With.C. the blank piller then prepared by step I is placed in fluid bed, and spray one deck medicament slow release skeleton solution, logical heat is empty
Air dry, and then spray one deck bonding skeleton agent solution, more logical hot-air dry; Repeat aforesaid operations, until medicine-feeding
Completely.
Prepared by III, slow releasing capsule
Slow-release pill Step II prepared incapsulates, and uses micropill automatic capsule filler, obtains tamsulosin hydrochloride sustained-release capsule, every hydrochloric tamsulosin 0.2mg of slow releasing capsule.
Comparative example 8
Preparation technology:
Take principal agent and the adjuvant of recipe quantity, the PVP30 of recipe quantity is dissolved in the alcoholic solution that 200ml ethanol is mixed with the PVP30 of 5%, the solution I that the tamsulosin hydrochloride adding recipe quantity makes it fully dissolve, 40 DEG C of decline solution I are slowly embraced on the surface of celphere, the piller being with medicine is obtained after drying, again the hypromellose of recipe quantity, acrylic resin RS30D, Pulvis Talci are added in 200ml ethanol and obtain homogeneous liquid, 40 DEG C are carried out coating, obtain tamsulosin hydrochloride slow-releasing granules, granule proceeded to conventional capsule and get final product.
Checking embodiment:
The drug release determination of comparative example 1-8, embodiment 1-11 gained tamsulosin hydrochloride sustained-release capsule
According to " slow, controlled release preparation guideline " in Pharmacopoeia of the People's Republic of China version (two) annex in 2010, with 0.25% sodium lauryl sulphate for release medium, get comparative example 1-8 embodiment 1-11 gained tamsulosin hydrochloride sustained-release capsule 3 respectively, the dissolution finally drawn is 3 average dissolutions, measure according to Pharmacopoeia of the People's Republic of China version annex XD first method in 2010, measure peak area by HPLC method, calculate drug level and cumulative release percentage rate (dissolution medium: 0.25% sodium lauryl sulphate).Measurement result is in table 1.
Table 1 tamsulosin hydrochloride sustained-release capsule release and related substance investigation table
Stability experiment:
The sample of embodiment and comparative example is placed in the stability test case of temperature 40 DEG C ± 2 DEG C, relative humidity 75% ± 5%, investigate the accelerated stability of 3 months, result is as following table:
Table 2 tamsulosin hydrochloride sustained-release capsule release and related substance investigation table
As can be seen from Table 1 and Table 2:
Do not dash forward in embodiment group and release phenomenon, and the result of extraction of embodiment 1 is better than other embodiment group, pH adjusting agent and HP-β-CD synergism improve release jointly.
In embodiment group, the content of related substance all meets pharmacopeia relevant requirements.
In the tamsulosin hydrochloride sustained-release capsule of comparative example 1,3,4 containing HP-β-CD or content too much very few time, its dissolution obviously reduces, and the content of related substance obviously increases.
Not containing pH adjusting agent in the tamsulosin hydrochloride sustained-release capsule of comparative example 2, the effect of final stripping is also affected.
Potassium dihydrogen phosphate pH adjusting agent the most in comparative example 5 medicated layer, does not contain HP-β-CD and adopts different preparation methoies; Comparative example 6 does not have potassium dihydrogen phosphate and HP-β-CD all not to reach technique effect of the present invention.
Comparative example 7 adopts lecithin protection, but affects the final dissolution of medicine.
Comparative example 8 prescription and technique are different from the present invention, and drug release process occurs dashing forward and releases phenomenon, and the dissolution before and after accelerated test is all lower than the present invention.
The content of the related substance of comparative example's group, all apparently higher than the present invention before and after accelerated test.
Claims (10)
1. a tamsulosin hydrochloride sustained-release capsule, is characterized in that, it is made up of celphere, medicated layer, sustained release coating, and wherein said celphere comprises microcrystalline Cellulose, sorbitol, starch, lactose; Described medicated layer comprises tamsulosin hydrochloride, pH adjusting agent, filler, binding agent; Described sustained release coating comprises slow-release material, plasticizer, porogen, antiplastering aid.
2. a kind of tamsulosin hydrochloride sustained-release capsule according to claim 1, is characterized in that, each component of this slow releasing capsule presses following weight percents composition:
3. a kind of tamsulosin hydrochloride sustained-release capsule according to claim 1, is characterized in that, each component of this slow releasing capsule presses following weight percents composition:
4. a kind of tamsulosin hydrochloride sustained-release capsule according to claim 1, is characterized in that, each component of this slow releasing capsule presses following weight percents composition:
5. a kind of tamsulosin hydrochloride sustained-release capsule according to claim 1, it is characterized in that, described slow-release material is: Eurdragit NE 30, methylcellulose, sodium carboxymethyl cellulose, hypromellose, polyvidone, carbopol, alginic acid sodium salt, chitosan, fat, wax class, stearic acid, hexadecanol, octadecanol, Polyethylene Glycol, ethyl cellulose, polyethylene, polypropylene, polysiloxanes, polysiloxanes, ethylene-vinyl acetate copolymer, polymethyl methacrylate wherein one or more.
6. a kind of tamsulosin hydrochloride sustained-release capsule according to claim 1, is characterized in that, described binding agent is: the one in hypromellose, PVP K30, carboxymethyl cellulose, water, ethanol, starch slurry; Described porogen is selected from polyvidone, Polyethylene Glycol, polyvinyl alcohol one; Described plasticizer is selected from one or more in propylene glycol, Oleum Ricini, Polyethylene Glycol, silicone oil, glycerol, diethyl phthalate or dibutyl ester diethyl phthalate, SA dibutyl ester and tri-n-butyl citrate.
7. a kind of tamsulosin hydrochloride sustained-release capsule according to claim 1, is characterized in that, described antiplastering aid is: the one in differential silica gel, silicon dioxide.
8. a kind of tamsulosin hydrochloride sustained-release capsule according to claim 1, it is characterized in that, described slow-release material is EurdragitNE 30, described binding agent is hypromellose, described antiplastering aid is differential silica gel, described porogen is selected from polyvidone, described plasticizer phthalic acid diethylester, and described filler is HP-β-CD.
9. the preparation method of a kind of tamsulosin hydrochloride sustained-release capsule according to claim 1, it is characterized in that, concrete operation step is as follows:
(1) get the microcrystal cellulose powder of recipe quantity, sorbitol, starch, lactose is put in centrifugal granulator, take water as adhesive, obtained 20 order particle diameters are the celphere of 0.5-2mm;
(2) configure binder aqueous solution, take pH adjusting agent by weight percentage, HP-β-CD is dissolved in binder aqueous solution;
(3) tamsulosin hydrochloride is dissolved in the solution in step (2), slowly stirs, obtain containing drug solns;
(4) celphere adds fluid bed, with step (3) containing drug solns coating, the pastille piller of obtained tamsulosin hydrochloride after dry;
(5) with 65 ~ 85% dissolve with ethanol solution slow-release material, plasticizer, porogen, antiplastering aid, make sustained release coating liquid;
(6) the pastille piller of tamsulosin hydrochloride adds fluid bed, and carry out coating with the coating solution that step (3) obtains, temperature controls to answer Keep agitation coating solution at 38-45 DEG C of coating process, the slow-release pill of obtained tamsulosin hydrochloride after dry;
(7) the tamsulosin hydrochloride slow-release pill that step (6) is obtained is incapsulated, the slow releasing capsule of obtained tamsulosin hydrochloride.
10. the preparation method of a kind of tamsulosin hydrochloride sustained-release capsule according to claim 8, is characterized in that, by weight calculating, in described step (2), the viscosity of configuration binder aqueous solution is 20mpa.s-35mpa.s, and concentration is 3-6%; By weight calculating, the concentration of described step (3) tamsulosin hydrochloride solution is 0.08-0.25%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510309268.8A CN104873478A (en) | 2015-06-06 | 2015-06-06 | Tamsulosin hydrochloride sustained-release capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510309268.8A CN104873478A (en) | 2015-06-06 | 2015-06-06 | Tamsulosin hydrochloride sustained-release capsule and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104873478A true CN104873478A (en) | 2015-09-02 |
Family
ID=53941336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510309268.8A Pending CN104873478A (en) | 2015-06-06 | 2015-06-06 | Tamsulosin hydrochloride sustained-release capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104873478A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108096220A (en) * | 2017-12-11 | 2018-06-01 | 苏州中化药品工业有限公司 | A kind of sustained-release preparation of tamsulosin hydrochloride and preparation method thereof |
| CN114469947A (en) * | 2022-03-22 | 2022-05-13 | 平顶山市妇幼保健院 | Application of novel antihistamine pharmaceutical preparation in laryngitis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005053659A1 (en) * | 2003-12-03 | 2005-06-16 | Natco Pharma Limited | An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation |
| CN101125134A (en) * | 2006-08-16 | 2008-02-20 | 常州市第四制药厂有限公司 | Hydrochloric tamsulosin sustained-release capsule and its preparation method |
| CN101204387A (en) * | 2006-12-19 | 2008-06-25 | 北京德众万全药物技术开发有限公司 | Novel tamsulosin hydrochloride sustained release capsules |
| CN101889996A (en) * | 2009-05-19 | 2010-11-24 | 张立英 | Rectal administration composition containing tamsulosin |
-
2015
- 2015-06-06 CN CN201510309268.8A patent/CN104873478A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005053659A1 (en) * | 2003-12-03 | 2005-06-16 | Natco Pharma Limited | An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation |
| CN101125134A (en) * | 2006-08-16 | 2008-02-20 | 常州市第四制药厂有限公司 | Hydrochloric tamsulosin sustained-release capsule and its preparation method |
| CN101204387A (en) * | 2006-12-19 | 2008-06-25 | 北京德众万全药物技术开发有限公司 | Novel tamsulosin hydrochloride sustained release capsules |
| CN101889996A (en) * | 2009-05-19 | 2010-11-24 | 张立英 | Rectal administration composition containing tamsulosin |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108096220A (en) * | 2017-12-11 | 2018-06-01 | 苏州中化药品工业有限公司 | A kind of sustained-release preparation of tamsulosin hydrochloride and preparation method thereof |
| CN114469947A (en) * | 2022-03-22 | 2022-05-13 | 平顶山市妇幼保健院 | Application of novel antihistamine pharmaceutical preparation in laryngitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021215272A1 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
| CN104606146B (en) | A kind of esomeprazole enteric capsules preparation and preparation method thereof | |
| CN1886119B (en) | Pantoprazole multiparticulate formulations | |
| RU2540494C2 (en) | Preparing dosage forms of controlled-release skeletal muscle relaxant | |
| US20200181291A1 (en) | Hypromellose acetate succinate powder excellent in dissolved state and production method thereof, and production methods for composition for solid dispersion, coating composition, drug-containing particle, and solid preparation | |
| WO2007082770A1 (en) | Coated formulations | |
| CN103585112A (en) | Tamsulosin enteric coated sustained-release pellet and preparation method thereof | |
| Alhalmi et al. | Sustained release matrix system: an overview | |
| WO2006005512A1 (en) | Granules for controlled release of tamsulosin | |
| CN101646422A (en) | Extended-release dosage form | |
| CN109789102A (en) | The preparation with improvement pH dependent drug release characteristics comprising esomeprazole or its pharmaceutically acceptable salt | |
| CN104873478A (en) | Tamsulosin hydrochloride sustained-release capsule and preparation method thereof | |
| CN105073100A (en) | Pharmaceutical compositions of tamsulosin or salts thereof | |
| CN109646412A (en) | A kind of enteric Pharmaceutical composition and its preparation method and application | |
| CN105326801B (en) | A kind of preparing process and application method of esomeprazole enteric coating liquid | |
| CN101229141B (en) | Aspirin sustained release tablet and preparing method thereof | |
| CN108371657A (en) | A kind of preparation method of esomeprazole enteric capsules | |
| CN101669912A (en) | Slow-release composition containing tamsulosin and preparation thereof | |
| CN105769786A (en) | Mirabegron sustained release tablet and preparation method thereof | |
| CN104758937A (en) | Metoprolol sustained-release pellet preparation | |
| JP6695013B1 (en) | Binder | |
| CN103919735A (en) | Tamsulosin hydrochloride sustained-release pellet and preparation method thereof | |
| CN103381148A (en) | Solid preparation including finasteride and preparation method thereof | |
| CN102579392A (en) | Slow-release preparation containing tamsulosin hydrochloride and preparation method thereof | |
| CN103211770B (en) | A kind of Ailamode slow release multicomponent composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination |